Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.98 USD

16.98
6,213,790

+0.17 (1.01%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $16.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges

by Kinjel Shah

The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products

FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension

by Zacks Equity Research

Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.

Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes

by Zacks Equity Research

Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.

Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.

Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates

by Zacks Equity Research

Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.

Teva (TEVA) Q2 Earnings Beat, Sales Miss, Keeps 2020 View

by Zacks Equity Research

Teva beats estimates for earnings while missing the same for sales in second-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.

Teva (TEVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Indrajit Bandyopadhyay headshot

Uncertainty Looms Large Over Generic Drug Industry Players

by Indrajit Bandyopadhyay

Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.

The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries

Sejuti Banerjea headshot

Sometimes, Valuation Is the Most Important Consideration

by Sejuti Banerjea

It pays to check the valuation before investing because it isn't always the best companies that have upside potential.

FDA Advisory Committee to Review Mallinckrodt'sTerlipressin

by Zacks Equity Research

Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.

Endo (ENDP) Obtains FDA Approval for Cellulite Treatment

by Zacks Equity Research

Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.

Sumit Singh headshot

Pick These 4 Low P/CF Stocks for a Balanced Portfolio in 2H

by Sumit Singh

Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.

Kinjel Shah headshot

Choose These 5 Price-to-Book Value Stocks for High Returns

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (TEVA) Outperforming Other Medical Stocks This Year?

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Novartis Discontinues HCQ Study Due to Enrollment Challenges

by Zacks Equity Research

Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

Kinjel Shah headshot

FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus

by Kinjel Shah

The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.

Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (TEVA) Outperforming Other Medical Stocks This Year?

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $11.25, moving -0.71% from the previous trading session.

Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan

by Zacks Equity Research

Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.

Novartis' sBLA for Ofatumumab Gets Extended Review From FDA

by Zacks Equity Research

The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.

Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.